Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-70
SponsorMansoura University
About this trial
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Portal vein thrombosis, Cirrhosis, With or without HCC, Child A & B
Disqualifiers
Platelets<10000, Createnine >1.9, Budd ciarri, Uncontrolled active bleeding
Trial design
Design model
Parallel
Treatments tested in this trial
Enoxaparin, warfarrin, or apixaban
DrugEnoxaparin, warfarrin, or apixaban
Treatment groups
100 Participants
are divided into 3 treatment groupsGroup A: Anticoagulant in cirrhosis with HCCExperimental treatment 1 intervention
Group B: Anticoagulant in Cirrhosis without HCCExperimental treatment 1 intervention
Group C: No anticoagualnt in Cirrhosis with or without HCCNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Portal vein thrombosis
determine if thrombus resolved or not on anticcoagulant by triphasic CT
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov